mRNA bivalents COVID-19 vaccine
Sponsors
National Research Council of Thailand (NRCT)
Conditions
Primary Objectives:
To evaluate the antibody responses and long-term immunogenicity both humoral and T-cell response after boosting of bivalent mRNA vaccine approximately one year of those who have previously received two doses of Sinovac or Sinoharm and third or forth doses of COVID vaccines of any platforms during the current Omicrons variants.
Safety
To assess the safety and tolerability of the mRNA booster dose
Sinovac or Sinoharm and third or forth doses of COVID vaccines
mRNA boostThe primary objectives of the study
1. To evaluate humoral immune responses, T-cell response and durability among those who have had received 2 doses of NDV-HXP-S and heterogenous booster vaccines given after 12 months.
1.1.To assess the IgG immune response against the Spike protein measured by ELISA and compared with baseline (pre-boost titer), Days 28 and Days 90 following mRNA vaccination
1.2 To assess a subset for functional (neutralizing) humoral immune responses elicited as measured by
Phase 2
Immune responses of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike (NDV-HXP-S) with heterologous booster after 12 months in adults
Active, not recruitingTCTR20230809003
Start: 2023-06-06Target: 130Updated: 2026-08-03
Immune responses, boosting effects of adults previously received two doses of inactivated COVID-l9 vaccines and third doses of any COVID-I9 vaccine with additional mRNA COVID-19 vaccine boost after one year
Active, not recruitingTCTR20230811004
Start: 2023-06-06Target: 198Updated: 2026-08-03